29/06/2021 – 10:16
Vicente Larraga, who works at the Margarita Salas Biological Research Center of the Higher Council for Scientific Research (CIB-CSIC) and leads one of the main research groups that develops the Spanish vaccine against Covid-19, hopes that normality will reach Spain in autumn, but that the pandemic will extend “at least for two or three years,” he explained to EFEsalud. Thus, Spanish vaccines will have their place, especially if they offer any difference with respect to those already approved.
Vicente Larraga has shared with the media the characteristics, quality and competitiveness of the vaccine that he develops against the coronavirus. In fact, you are confident that your solution will be finished by the end of the year. But he is cautious: “This is an endurance race,” he says. “When we finish the preclinical phase? I hope it will be this summer? We will ask the European Medicines Agency for permission to allow us to start the clinical phase,” he adds.
In addition, the scientist believes that the vaccines that are being developed now must offer something new for any multinational to be interested in their distribution. In that sense, yours is kept at room temperature and can be quickly remade to adapt it to variants of the virus that are more resistant because it is a synthetic DNA vaccine.
“We use a synthetic DNA vehicle that mimics the mechanism of a virus to enter the cell and make it synthesize the protein of the gene we want, in this case the protein S or spike, which is the antigen (a substance that triggers the immune reaction) of the virus. In addition, we are testing a different protein, “he says.
It is a vaccine that is more similar to those of Pfizer and Moderna than the other two that are also being developed by the Higher Council for Scientific Research, based on viruses. Specifically, they are the projects of Luis Enjuanes and Mariano Esteban.